when does semaglutide come off patent Ozempic's Protection Starts to Expire in 2026. What Next? Off-patent semaglutide in 2026: the

Although amylase and lipase levels were numerically higher in the dulaglutide group during follow-up, clinically significant pancreatitis was rare, with only one case observed, likely related to gallstone disease rather than direct pharmacologic toxicity

Retatrutide remains an investigational medicinal product , meaning it is only legally available within the context of authorised clinical trials

The hallmark symptom of acute pancreatitis is severe, persistent abdominal pain , typically located in the upper abdomen (epigastric region) and often described as: Sudden onset and constant (not cramping or intermittent) Severe intensity that may worsen after eating Radiating through to the back or between the shoulder blades Accompanied by a tender abdomen when touched Associated symptoms that frequently occur alongside the abdominal pain include: Nausea and persistent vomiting Fever and rapid pulse Abdominal swelling or distension Loss of appetite Feeling generally unwell (malaise) It is crucial to distinguish pancreatitis symptoms from the common gastrointestinal side effects of GLP-1 agonists, which affect a significant proportion of users, particularly during treatment initiation

Case 2 A 74-year-old white man with a history of type II diabetes presented with an itchy rash on the bilateral flanks and lower abdomen for 3 weeks duration

Semaglutide, the generic name of these medications, was designed to help control blood sugar levels and promote improved overall health

These differences suggest that the choice of agent may depend on the specific ocular comorbidity and the patients baseline retinopathy status